CATX

Perspective Therapeutics Inc.

CIK 0000728387
Employees 163
Phone 206 676 0900
Fiscal year end December
IPO Nov 10, 2005
Address 2401 Elliott Avenue, Seattle, WA, United States, 98121
0.87
-0.01 (-1.11%)
USD · AMEX
52-week range
0.84
6.16
Trading at 1% of the 52-week range
Market Cap
99.33M
P/E Ratio
0.00
Forward P/E
25.71
Book Value
2.84
Div. Yield
N/A
% Institutions
86.03%
% Insiders
8.23%

1 Year

-62.7%

3 Year

-66.5%

10 Year

-83.9%
Description

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Actions

Add an action for CATX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Johan M. Spoor CEO & Director 1972
Mr. Joel David Sendek CFO & Principal Financial Officer 1967
Dr. Markus Puhlmann M.B.A., M.D. Chief Medical Officer 1966
Dr. Michael K. Schultz Ph.D. Co-Founder & Senior Scientific Advisor NA
Mr. Shane Cobb Executive Vice President of Operations NA
Mr. Jonathan R. Hunt Chief Accounting Officer 1967
Dr. Paul Lyne Ph.D. Chief Science Officer NA
Ms. Annie J. Cheng Vice President of Investor Relations 1976
Mr. Chris Nenno General Counsel & Corporate Secretary NA
Mr. Andrew Bright Executive Vice President of Brachytherapy NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Nov 13, 2025 Jonathan Robert Hunt N/A Purchase 11.00K $2.03 $22.33K SEC
Nov 12, 2025 Robert F Williamson III N/A Purchase 9.50K $2.10 $19.95K SEC

Financial Highlights

▼
Market Cap: $99.33M
EBITDA: $-121.19M
Book Value: $2.84
Earnings/Share: $-1.33
Profit Margin: 0.00%
Operating Margin: -36,120.99%
ROA (TTM): -22.28%
ROE (TTM): -39.57%
Revenue (TTM): $409.00K
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -72.10%

Valuation Metrics

Enterprise Value: $-114.20M
Trailing P/E: 0.00
Forward P/E: 25.71

Shares Statistics

Shares Outstanding: 114.15M
Shares Float: 70.82M
% Insiders: 8.23%
% Institutions: 86.03%
Shares Short: 16.68M
Shares Short (Prior Month): 22.81M
Short Ratio: 6.96
Short % Float: 17.45%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$884.00K
Cost of Goods Sold
adjust
$-3.25M
Gross Profit
subtotal
$-2.37M
SG&A
adjust
$-30.23M
R&D
adjust
$-84.22M
Operating Income
subtotal
$-113.56M
Other / Non-Operating Items
adjust
$10.44M
Net Income
subtotal
$-103.12M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CATX.US!